Cash & Equivalents
Amgen Cash & Equivalents increased by 1138.7% to $9.13B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 23.8%, from $11.97B to $9.13B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 7.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Detailed definition
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Peer comparison
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $923.00M | $646.00M | $7.99B | $691.00M | $770.00M | $557.00M | $7.63B | $496.00M | $630.00M | $533.00M | $10.94B | $471.00M | $489.00M | $435.00M | $11.97B | $508.00M | $542.00M | $737.00M | $9.13B |
| QoQ Change | — | -30.0% | >999% | -91.4% | +11.4% | -27.7% | >999% | -93.5% | +27.0% | -15.4% | >999% | -95.7% | +3.8% | -11.0% | >999% | -95.8% | +6.7% | +36.0% | >999% |
| YoY Change | — | — | — | — | -16.6% | -13.8% | -4.5% | -28.2% | -18.2% | -4.3% | +43.5% | -5.0% | -22.4% | -18.4% | +9.4% | +7.9% | +10.8% | +69.4% | -23.8% |
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Amgen's cash & equivalents?
- Amgen (AMGN) reported cash & equivalents of $9.13B in Q4 2025.
- How has Amgen's cash & equivalents changed year-over-year?
- Amgen's cash & equivalents decreased by 23.8% year-over-year, from $11.97B to $9.13B.
- What is the long-term trend for Amgen's cash & equivalents?
- Over 5 years (2020 to 2025), Amgen's cash & equivalents has grown at a 7.8% compound annual growth rate (CAGR), from $6.27B to $9.13B.
- What does cash & equivalents mean?
- Money in the bank and very short-term investments that can be turned into cash almost instantly.